ADXN
NASDAQ
CH
Addex Therapeutics Ltd - American Depositary Shares
$5.72
▼ $-0.56
(-8.92%)
Vol 9K
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$8.1M
ROE
-73.2%
Margin
-1026.7%
D/E
0.61
Beta
-0.16
52W
$0–$0
Wall Street Consensus
9 analysts · Jan 20260
Strong Buy
0
Buy
2
Hold
5
Sell
2
Strong Sell
0.0%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 25.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2024 | — | $-1.23 | — |
| Dec 2022 | — | $-0.23 | — |
| Jun 2013 | $-0.64 | $-1.61 | $-0.97 |
| Dec 2012 | $-1.61 | $-1.55 | +$0.06 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | $54K | $2K | — | — | $30K |
| Net Income | -$1.5M | -$1.2M | -$1.5M | -$1.8M | -$1.6M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -62.4% | 87.0% | 87.0% | -62.4% | -62.4% | -73.2% |
| P/E (TTM) | — | 1.19 | 0.76 | — | — | — |
| Net Margin | -5060.9% | 1410.4% | 1410.4% | -1002.4% | -1002.4% | -1026.7% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.53 | 0.48 | 0.48 | 0.53 | 0.53 | 0.61 |
| Current Ratio | 2.31 | 3.03 | 3.03 | 2.31 | 2.31 | 2.01 |
Key Ratios
ROA (TTM)
-63.3%
P/S (TTM)
14.52
P/B
1.1
EPS (TTM)
$-0.06
CF/Share
$-0.21
Rev Growth 3Y
-49.3%
52W High
$0.09
52W Low
$0.05
$0.05
52-Week Range
$0.09
Financial Health
Free Cash Flow
-$533K
Net Debt
-$2.2M
Cash
$2.2M
Total Debt
$37K
As of Sep 30, 2025
How does ADXN compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
ADXN valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
14.5
▲
193%
above
peers
(5.0)
vs Peers
vs Industry
Pricier
P/B ratio
1.1
▼
49%
below
peers
(2.1)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
ADXN profitability vs Pharmaceuticals peers
ROE
-73.2%
▼
35%
below
peers
(-54.3%)
vs Peers
vs Industry
Below avg
Net margin
-1026.7%
▼
2067%
below
peers
(-47.4%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(68.3%)
vs Peers
vs Industry
In line
ROA
-63.3%
▼
69%
below
peers
(-37.4%)
vs Peers
vs Industry
Weak
ADXN financial health vs Pharmaceuticals peers
D/E ratio
0.6
▼
60%
below
peers
(1.5)
vs Peers
vs Industry
Above avg
Current ratio
2.0
▼
40%
below
peers
(3.4)
vs Peers
vs Industry
Low liquidity
Beta
-0.2
▼
117%
below
peers
(0.9)
vs Peers
vs Industry
More volatile
ADXN fundamentals radar
ADXN
Peer median
Industry
ADXN profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
ADXN vs peers: key metrics
Top Holders
Top 5: 0.03%Morgan Stanley
0.02%
$2K
UBS Group AG
0.01%
$1K
Gamma Investing LLC
$542
Rhumbline Advisers
$482
SBI Securities Co., Ltd.
$6
As of Dec 31, 2025
Latest News
No related news yet